324 related articles for article (PubMed ID: 12134947)
21. Transport characteristics of peptidomimetics. Effect of the pyrrolinone bioisostere on transport across Caco-2 cell monolayers.
Sudoh M; Pauletti GM; Yao W; Moser W; Yokoyama A; Pasternak A; Sprengeler PA; Smith AB; Hirschmann R; Borchardt RT
Pharm Res; 1998 May; 15(5):719-25. PubMed ID: 9619780
[TBL] [Abstract][Full Text] [Related]
22. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.
Ma L; Qin Y; Shen Z; Bi H; Hu H; Huang M; Zhou H; Yu L; Jiang H; Zeng S
J Ethnopharmacol; 2015 Aug; 172():430-5. PubMed ID: 26183576
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model.
Karyekar CS; Eddington ND; Garimella TS; Gubbins PO; Dowling TC
Pharmacotherapy; 2003 Apr; 23(4):436-42. PubMed ID: 12680473
[TBL] [Abstract][Full Text] [Related]
24. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.
Dahan A; Sabit H; Amidon GL
AAPS J; 2009 Jun; 11(2):205-13. PubMed ID: 19319690
[TBL] [Abstract][Full Text] [Related]
25. Optimizing oral absorption of peptides using prodrug strategies.
Borchardt RT
J Control Release; 1999 Nov; 62(1-2):231-8. PubMed ID: 10518655
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines.
Mukkavilli R; Jadhav G; Vangala S
Curr Pharm Biotechnol; 2017; 18(14):1151-1158. PubMed ID: 29521222
[TBL] [Abstract][Full Text] [Related]
27. Dipeptide prodrug approach to evade efflux pumps and CYP3A4 metabolism of lopinavir.
Patel M; Sheng Y; Mandava NK; Pal D; Mitra AK
Int J Pharm; 2014 Dec; 476(1-2):99-107. PubMed ID: 25261710
[TBL] [Abstract][Full Text] [Related]
28. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
Mease K; Sane R; Podila L; Taub ME
J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
[TBL] [Abstract][Full Text] [Related]
29. [Absorption and transport of isoflavonoid compounds from Tongmai formula across human intestinal epithelial (Caco-2) cells in vitro].
Wang FR; Yang XW
Zhongguo Zhong Yao Za Zhi; 2017 Aug; 42(16):3206-3212. PubMed ID: 29171242
[TBL] [Abstract][Full Text] [Related]
30. Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells.
Balimane PV; Chong S; Patel K; Quan Y; Timoszyk J; Han YH; Wang B; Vig B; Faria TN
Arch Pharm Res; 2007 Apr; 30(4):507-18. PubMed ID: 17489369
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the permeation characteristics of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs across the blood-brain barrier using an in situ perfused rat brain model.
Chen W; Yang JZ; Andersen R; Nielsen LH; Borchardt RT
J Pharmacol Exp Ther; 2002 Nov; 303(2):849-57. PubMed ID: 12388672
[TBL] [Abstract][Full Text] [Related]
32. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
33. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
Guo A; Marinaro W; Hu P; Sinko PJ
Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
[TBL] [Abstract][Full Text] [Related]
34. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate.
Tolle-Sander S; Rautio J; Wring S; Polli JW; Polli JE
Pharm Res; 2003 May; 20(5):757-64. PubMed ID: 12751631
[TBL] [Abstract][Full Text] [Related]
35. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
36. Transcellular and lipophilic complex-enhanced intestinal absorption of human growth hormone.
Wu SJ; Robinson JR
Pharm Res; 1999 Aug; 16(8):1266-72. PubMed ID: 10468030
[TBL] [Abstract][Full Text] [Related]
37. The effect of conformation of the acyloxyalkoxy-based cyclic prodrugs of opioid peptides on their membrane permeability.
Gudmundsson OS; Vander Velde DG; Jois SD; Bak A; Siahaan TJ; Borchardt RT
J Pept Res; 1999 Apr; 53(4):403-13. PubMed ID: 10406218
[TBL] [Abstract][Full Text] [Related]
38. Coumarinic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeability.
Gudmundsson OS; Pauletti GM; Wang W; Shan D; Zhang H; Wang B; Borchardt RT
Pharm Res; 1999 Jan; 16(1):7-15. PubMed ID: 9950272
[TBL] [Abstract][Full Text] [Related]
39. Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides.
Liederer BM; Fuchs T; Vander Velde D; Siahaan TJ; Borchardt RT
J Med Chem; 2006 Feb; 49(4):1261-70. PubMed ID: 16480263
[TBL] [Abstract][Full Text] [Related]
40. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.
Luo FR; Paranjpe PV; Guo A; Rubin E; Sinko P
Drug Metab Dispos; 2002 Jul; 30(7):763-70. PubMed ID: 12065434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
